Agios Pharmaceuticals (AGIO) Gross Profit (2017 - 2026)

Agios Pharmaceuticals has reported Gross Profit for 9 years, with the latest figure at $19.4 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 154.25% year-over-year to $19.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.5 million (up 83.48% YoY), and the FY2025 full-year result was $47.7 million, up 47.47% from the prior year.
• Gross Profit for Q1 2026 stood at $19.4 million, up from $18.1 million in the prior quarter.
• The five-year high for Gross Profit was $19.4 million in Q1 2026, with the low at $493000.0 in Q1 2022.
• Historically, Gross Profit has averaged $8.0 million across 5 years, with a median of $7.1 million in 2024.
• Annual changes were most pronounced in 2023 — Gross Profit jumped 925.35% — and 2025, when it grew 1.04%.
• Agios Pharmaceuticals' Gross Profit stood at $3.9 million in 2022, then soared by 67.23% to $6.5 million in 2023, then surged by 45.31% to $9.5 million in 2024, then soared by 91.0% to $18.1 million in 2025, then increased by 7.4% to $19.4 million in 2026.
• The last three Gross Profit figures came in at $19.4 million (Q1 2026), $18.1 million (Q4 2025), and $11.2 million (Q3 2025), per Business Quant data.